Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
9263376 | Diagnostic Microbiology and Infectious Disease | 2005 | 11 Pages |
Abstract
At an end point of â¥50% inhibition, the MIC-2s varied from 16 to 128 μg/mL for Mycograb® and from 0.125 to 16 μg/mL for fluconazole. The fractional inhibitory concentration index classified the combination as indifferent for 5 isolates, additive for 3 more isolates, and synergistic in a single isolate. Time-kill analysis on 2 isolates (F/7844 and F/10156), which had synergistic and additive results with amphotericin B, respectively, on checkerboard was performed with 4-16 μg/mL of Mycograb®, 2-8 μg/mL of fluconazole, and 0.0625-2 μg/mL of amphotericin B. This demonstrated an increasingly static effect with augmenting concentrations of fluconazole and an initial static effect with amphotericin B at lower concentrations, which became fungicidal as the level of drug increased. The addition of either 4 or 8 μg/mL of Mycograb® to 0.5 μg/mL of amphotericin B with C. neoformans F/7844 changed a static effect to a fungicidal effect at 8 h with an increased killing of 1.2 logs at 48 h. With C. neoformans F/10156, the addition of 16 μg/mL of Mycograb® to 0.25 μg/mL of amphotericin B produced a difference in killing from 1 logarithm after 4 h to 1.5 logarithms after 48 h. These data suggest that the combination of amphotericin B and Mycograb® would be worth exploring in the treatment of infection due to C. neoformans.
Keywords
Related Topics
Life Sciences
Immunology and Microbiology
Applied Microbiology and Biotechnology
Authors
Lucy Nooney, Ruth C. Matthews, James P. Burnie,